Cowen & Co. Assigns a Buy Rating on Galapagos NV


Cowen & Co. analyst Phil Nadeau assigned a Buy rating to Galapagos NV (NASDAQ: GLPG) yesterday. The company’s shares opened today at $101.83.

According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 15.1% and a 57.9% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Rhythm Pharmaceuticals Inc, and Voyager Therapeutics Inc.

Currently, the analyst consensus on Galapagos NV is Moderate Buy and the average price target is $118, representing a 15.9% upside.

In a report released yesterday, BTIG also reiterated a Buy rating on the stock with a $118 price target.

See today’s analyst top recommended stocks >>

Based on Galapagos NV’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $45.82 million. In comparison, last year the company had a GAAP net loss of $14.57 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. It operates through the Research and Development and Fee-for-Services segment. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts